Invesco’s Avalo Therapeutics AVTX Stock Holding History

Invesco’s Portfolio AVTX Stock Details AVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$411K	Buy	+22,226	New	+$351K	﹤0.01%	3319
2022 Q2	–	Sell	-7	Closed	-$14K	–	4046
2022 Q1	$14K	Hold	7	–	–	﹤0.01%	3996
2021 Q4	$33K	Hold	7	–	–	﹤0.01%	4007
2021 Q3	$41K	Buy	7 +2	+40%	+$16.2K	﹤0.01%	4006
2021 Q2	$45K	Sell	5 -4	-44%	-$33.5K	﹤0.01%	3952
2021 Q1	$76K	Hold	9	–	–	﹤0.01%	3793
2020 Q4	$71K	Sell	9 -5	-36%	-$34.7K	﹤0.01%	3692
2020 Q3	$90K	Sell	14 -11	-44%	-$82.7K	﹤0.01%	3578
2020 Q2	$188K	Buy	25 +4	+19%	+$29K	﹤0.01%	3490
2020 Q1	$149K	Buy	21 +3	+17%	+$31.7K	﹤0.01%	3483
2019 Q4	$280K	Sell	18 -1	-5%	-$10.5K	﹤0.01%	3444
2019 Q3	$177K	Hold	19	–	–	﹤0.01%	3569
2019 Q2	$300K	Sell	19 -13	-41%	-$197K	﹤0.01%	3502
2019 Q1	$540K	Sell	32 -12	-27%	-$180K	﹤0.01%	3282
2018 Q4	$412K	Sell	44 -6	-12%	-$66.9K	﹤0.01%	3350
2018 Q3	$668K	Buy	50 +24	+92%	+$315K	﹤0.01%	3312
2018 Q2	$327K	Buy	+26	New	+$310K	﹤0.01%	3566

Other funds holding AVTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Invesco's AVTX Position: Q2 2026 in Review

Invesco opened a new position in Avalo Therapeutics (AVTX) in Q2 2026: 22,226 shares worth $411K. The stake represents ﹤0.01% of the portfolio and ranks #3319 among its holdings. This is a return to the name: Invesco previously reported a position in AVTX as recently as Q1 2022.

Invesco first reported a position in AVTX in Q2 2018 and has held it in 17 quarters since. The position peaked at $668K in Q3 2018. 125 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

Invesco held 22,226 shares of Avalo Therapeutics worth $411K as of Q2 2026.
Avalo Therapeutics was a new Invesco position in Q2 2026.
Avalo Therapeutics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #3319 holding.
Invesco first reported a position in Avalo Therapeutics in Q2 2018 and has held it in 17 quarters since.
Invesco's Avalo Therapeutics position peaked at $668K in Q3 2018.
125 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.